Skip to main content

Table 3 Quality of life in breast cancer patients before and after intervention in KD group and control group as measured by the EORTC QLQ-C30

From: Does a ketogenic diet have beneficial effects on quality of life, physical activity or biomarkers in patients with breast cancer: a randomized controlled clinical trial

Symptomsa KD Control p-value
Fatigue
 Week 0 22(8–33)a 33(11–44) 0/10
 Week 12 33(19–55) 33(33–55) 0/66
p-value 0/01 0/02  
Nausea and vomiting
 Week 0 0(0–0) 0 (0–20) 0/21
 Week 12 0(0–4) 16(0–16) 0/64
p-value 0/01 0/02  
Pain
 Week 0 16(0–50) 16(0–33) 0/59
 Week 12 16(0–50) 33(16–50) 0/59
p-value 0/62 0/38  
Reduction in appetite
 Week 0 0(0–8) 0(0–33) 0.37
 Week 12 33(0–33) 16(0–33) 0.48
p-value 0.02 0.41  
Sleep difficulties
 Week 0 16(0–33) 0(0–66) 1
 Week 12 0(0–41) 33(0–50) 0/81
p-value 0/63 0/88  
Dyspnea
 Week 0 0(0–33) 0(0–33) 0/31
 Week 12 33(0–41) 16(0–33) 0/43
p-value 0.05 0.73  
Constipation
 Week 0 0 (0–0) 0 (0–33) 0.24
 Week 12 0 (0–33) 0 (0–33) 0.51
p-value 0/18 0/39  
Diarrhea
 Week 0 0 (0–0) 0 (0–0) 0.92
 Week 12 0 (0–33) 0 (0–0) 0/65
p-value 0.71 0.20  
Financial concerns
 Week 0 0 (0–0) 0 (0–0) 0.49
 Week 12 0 (0–33) 33 (0–58) 0.28
p-value 0.71 0.01  
  1. Mann–Whitney U test was used to compare the continuous variables between the two groups. Wilcoxon was used to compare the continuous variables within the two groups
  2. aThe higher values indicate a higher grade of symptoms Data shown as median and quartile (25, 75)